Pay in 4 interest-free payments of $5.52 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Table of Contents Is Tirzepatide a GLP-1
For researchers who want the convenience of a pre-formulated topical product, PSPeptides offers the GHK-Cu Spray for ready-to-use topical copper peptide application
The peptide is supplied as a lyophilized powder, a stable format suitable for analytical work, molecular research, and controlled experiments
Get your discount code, early access to new compounds, and protocol insights
Hengrui and Kailera report positive phase 3 results for dual GLP-1/GIP agonist in obesity treatment HRS9531 achieves significant weight reduction in Phase 3 trial, with plans for NDA submission in China and global development as KAI-9531 Hengrui Pharma and Kailera Therapeutics, have announced positive topline results from the Phase 3 clinical trial (HRS9531-301) of HRS9531, a once-weekly injectable dual GLP-1/GIP receptor agonist for adults with obesity or overweight
doi: 10.1016/S2213-2600(15)00043-0, 4
US$ 27.49
US$ 21.50
US$ 27.79
